![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 30, 21319-21325, July 23, 1999
From the Department of Physiology and Biophysics, Case Western
Reserve University School of Medicine, Cleveland, Ohio 44106-4970 and
the Hmu O, a heme degradation enzyme in the pathogen
Corynebacterium diphtheriae, catalyzes the
oxygen-dependent conversion of hemin to biliverdin, carbon
monoxide, and free iron. A bacterial expression system using a
synthetic gene coding for the 215-amino acid, full-length Hmu O has
been constructed. Expressed at very high levels in Escherichia
coli BL21, the enzyme binds hemin stoichiometrically to form a
hexacoordinate high spin hemin-Hmu O complex. When ascorbic acid is
used as the electron donor, Hmu O converts hemin to biliverdin with
Heme oxygenase (HO),1
first characterized in eukaryotes, is an enzyme that catalyzes the
regiospecific oxidative degradation of iron protoporphyrin IX to
biliverdin IX Among the well characterized isoforms of the mammalian HO are HO-1,
which is 33 kDa, inducible, and highly expressed in the spleen and
liver, and HO-2, which is 36 kDa, constitutive, and found primarily in
the brain and testes (2). Both isoforms function similarly in their
catalytic cycle (5). HO first binds hemin stoichiometrically to form a
hemin-HO complex. Then, an electron donated from NADPH-cytochrome P-450
reductase reduces the hemin iron to the ferrous state (7). This allows
dioxygen to bind to the ferrous iron, forming a metastable oxy complex (8). Additional electron donation to this oxy complex initiates the
conversion of the heme to biliverdin IX Iron is required for the survival of most bacteria and is particularly
essential for pathogens to cause diseases (15-17). To circumvent the
low concentration of free extracellular iron, pathogenic bacteria have
developed sophisticated systems to acquire iron from iron-containing
proteins found in their hosts (17-20). One mechanism is via a
bacterial heme degradation enzyme (18, 21). In contrast to the
mammalian HO, whose primary purpose is to maintain iron homeostasis,
that of the bacterial HO is to release iron from heme so that the iron
may be utilized. Within the last few years, through genetic studies,
the presence of heme-degrading enzymes has been identified in
pathogenic bacteria (17, 21-22).
Hmu O, the first and only prokaryotic HO isolated to date, is expressed
by the hmu O gene found in Corynebacterium
diphtheriae, the causative agent of diphtheria. In comparison to
the mammalian HO, Hmu O is not membrane-bound but soluble and has a
smaller molecular mass of 24 kDa. It is 33% identical in sequence to
the first 221 amino acids of human HO-1 (22). This enzyme has been proposed to be utilized by C. diphtheriae to release iron
from the heme supplied by the pathogen's host. Using an
Escherichia coli expression system, Wilks and Schmitt (23)
have purified a 24-kDa Hmu O protein that stoichiometrically binds
hemin and converts it to biliverdin IX In this study, we have constructed a highly efficient bacterial
expression system of Hmu O using a synthetic gene based on the
hmu O gene sequence (22). We have examined the heme
degradation reaction catalyzed by Hmu O using the hemin-,
Construction of the Bacterial Heme Oxygenase Hmu O Expression
Plasmid, pMWHmuO
pMWA was excised with NdeI and XhoI, and the
resulting larger fragment of the digests was gel-purified. Using
T4 ligase, both Oligos I and II were ligated simultaneously
between the NdeI and XhoI sites of the
NdeI/XhoI fragment. The resulting plasmid, pMWB, was cleaved with XhoI and ClaI, and the larger
fragment was gel-purified. Both Oligos III and IV were ligated between
the XhoI and ClaI sites of the larger
XhoI/ClaI fragment, and pMWC was obtained. Excised by ClaI and AvrII, the larger
ClaI/AvrII fragment from pMWC was gel-purified
and ligated with Oligos V and VI simultaneously. The ligation of these
fragments yielded pMWD, which then was cut with AvrII and
HindIII. Oligos VII and VIII were ligated to the larger
AvrII/HindIII fragment from pMWD. Ligation of
Oligos VII and VIII resulted in the formation of pMWHmuO, the
expression plasmid for the recombinant bacterial heme oxygenase Hmu O
of C. diphtheriae. The nucleotide sequence was determined by
an Applied Biosystems 373A DNA sequencer. Fig.
1 is a comparison of the coding sequence
of the synthetic gene to that of the cloned DNA (22).
Protein Expression and Purification
Thawed on ice, the cell pellets were resuspended in 100 mM
Tris buffer, pH 8, containing 100 mM NaCl and 1 mM EDTA. Lysozyme (2 mg/g cells) and phenylmethysulfonyl
fluoride of final concentration 1 mM were added to the
resuspension, which was stirred continuously at 4 °C for 2 h.
The cells then were sonicated (Branson 450 Sonifier) until no longer
viscous and centrifuged at 39,000 × g for 1 h. The resulting supernatant was recovered for further purification.
Solid ammonium sulfate was added to the supernatant to a concentration
of 60% saturation, and the solution was stirred for 30 min at 4 °C.
After centrifugation at 14,000 × g for 30 min, the
supernatant then was increased to 85% ammonium sulfate saturation and
centrifuged. The subsequent precipitates, which contained the Hmu O
protein, were dissolved in 20 mM phosphate buffer, pH 7. The dissolved solution was gel-filtered through a Sephadex G75 column,
which had been equilibrated with 20 mM phosphate buffer, pH
7. Fractions with A400 nm greater than 0.35 were
pooled and loaded onto a column of DEAE-cellulose equilibrated with 20 mM phosphate buffer, pH 7. Eluted in 20 mM
phosphate buffer, pH 7, with a linear gradient of 0 to 0.4 M KCl, fractions with
A400 nm/A280 nm values
greater than 0.3 were pooled and concentrated by ultrafiltration. The
enzyme was stored at 77 K until use.
Reconstitution of Hmu O with Hemin Formation of the Reaction of the Hemin-Hmu O Complex with Ascorbic
Acid
For experiments performed with CO, the hemin-Hmu O complex was prepared
as described above but injected into a sealed cuvette filled with
phosphate buffer that had been presaturated with 50% CO and 50%
O2. Ascorbic acid of final concentration 17.5 mM was added to initiate heme degradation. The formation of
the verdoheme-CO complex was monitored spectrophotometrically. When
there was no further change in the spectrum, pyridine (20% final
concentration) was added to the mixture (28), and the formation of the
pyridine-verdoheme complex was recorded.
In other experiments, after the reaction had been arrested at the
verdoheme-CO stage, the verdoheme that had accumulated in the presence
of CO was allowed to continue to the fully oxidized product by
displacing the CO with 100% O2.
Reaction of the Heme-Hmu O Complex with
H2O2 and mCPBA Analytical Methods Expression and Purification of Hmu O
Using pMWHmuO, we have expressed successfully a recombinant Hmu O
protein, as depicted in the SDS-PAGE (Fig.
2, lane 2). The initial
expression of Hmu O by culturing the transformed BL21 cells at 37 °C
resulted in an accumulation of the expressed protein mostly in
inclusion bodies. Solubilization of the inclusion bodies, following the
methods used for mammalian HO mutants (32), successfully yielded an
active Hmu O. However, our current method of culturing the E. coli at 37 °C then 25 °C, instead of 37 °C continuously, has increased significantly the yield of the protein in the soluble form. Both the purified Hmu O in the soluble form and from inclusion bodies have the same enzymatic properties and optical absorption spectra. Our expression of Hmu O mostly in the soluble form has facilitated the purification process and yields 100-120 mg of purified
Hmu O/liter of bacterial culture, 5-fold greater than that reported by
Wilks and Schmitt (23). As indicated by SDS-PAGE, the purified Hmu O we
obtain is homogeneous and has a single band at 24 kDa (Fig. 2,
lane 3), the size as expected from the deduced Hmu O amino
acid sequence (24.1 kDa) (22). The pI value estimated by
isoelectricphoresis is 5.4.
We have observed that the transformed E. coli cultured at
37 °C are pale yellow, whereas those cultured at 37 °C then
25 °C are green. The former is because of the expressed protein
being in mostly inclusion bodies, whereas the latter is in the soluble form. The green E. coli cells indicate that biliverdin has
been formed from the hemin degradation catalyzed by the expressed Hmu O
and a reductase system in the E. coli, a phenomenon observed also for the E. coli expression of mammalian HO isoforms
(29, 32-33). During the purification of Hmu O, even after
DEAE-cellulose column chromatography, the fractions with the heme
oxygenase enzyme activity have a broad Soret band between 380 and 400 nm, indicating that biliverdin is bound to Hmu O. In the case of rat
HO-1, most of the biliverdin is removed by the DEAE-cellulose. Thus,
the biliverdin affinity of Hmu O appears to be higher than that of rat
HO-1. However, despite biliverdin being attached to the enzyme, hemin
still binds to Hmu O readily, as described below. This indicates that
biliverdin bound to Hmu O can be easily displaced by hemin, contrary to
that claimed by Wilks and Schmitt (23).
Properties of the Hemin-Hmu O Complex
Because the Soret region of the optical absorption spectrum of the
hemin-Hmu O complex is different from that of free hemin in pH 7 buffer, spectrophotometric titration of Hmu O with hemin was carried
out utilizing this difference. Illustrated in the inset of
Fig. 3, the titration curve of Hmu O with hemin has a well defined
inflection point. From this, the molar stoichiometry of their binding
has been established to be 1:1, which is in agreement with that
reported by Wilks and Schmitt (23). By the pyridine hemochrome method
(35), the extinction coefficient at 404 nm for the hemin-Hmu O complex
is determined to be 150 mM Degradation of the Hemin Bound to Hmu O with Ascorbic
Acid
In previous HO-1 studies, Yoshida and Kikuchi (12) observed that when
ascorbic acid was used as the electron donor, the heme degradation
product was not biliverdin but an Fe3+-biliverdin complex.
This differs from the Hmu O system, in which biliverdin, not the
Fe3+-biliverdin complex, is the final product of the
ascorbic acid-supported heme degradation. The implication of this is
that iron is more readily extruded in the Hmu O system in contrast to
the mammalian HO. This appears to be consistent with the physiological
role of Hmu O, which is to release iron from heme for iron utilization by the bacteria (23).
Formation of the Verdoheme-CO Complex Using Ascorbic
acid
Prolonged incubation of the bacterial verdoheme-CO complex in the 50%
CO and 50% O2 environment does not change its spectrum. When the CO and O2 mixture is replaced with 100%
O2, the optical absorption spectrum of the reaction product
(Fig. 5A, spectrum b) becomes similar to that
obtained by the ascorbic acid reaction of the hemin-Hmu O complex in
the absence of CO (Fig. 5A, spectrum c).3 The likeness of the two
spectra indicates that the originally CO-bound verdoheme-Hmu O complex
has converted to biliverdin and that verdoheme is a precursor to
biliverdin in Hmu O catalysis.
The formation of the verdoheme intermediate during the Hmu O-catalyzed
heme degradation reaction is further corroborated by the optical
absorption spectrum of Hmu O complexed with a chemically synthesized
verdoheme. The spectrum of the CO-bound ferrous verdoheme IX Reaction of the
Reaction of the ferrous CO-bound Reactions of the Hemin-Hmu O Complex with mCPBA and
H2O2--
In a previous study, to identify the
active intermediate in the first oxygenation step of HO catalysis,
which is the conversion of hemin to
In the case of the mammalian HO, a ferric hydroperoxide
(Fe3+-OOH) species has been proposed to be an active
intermediate in the first oxygenation step (29). Unlike
mCPBA, H2O2 hydroxylates the
We have also found that the extent of conversion to verdohemin is
dependent on the H2O2 concentration, with 5 equivalents of H2O2 inducing the most change,
and 1 equivalent, the least. In comparison to the
H2O2 reactions with rat HO-1 (Fig.
8B), those with Hmu O are less efficient and do not result
in the virtual loss of the Soret band. Even with 1 equivalent of
H2O2, verdoheme formation by rat HO-1 is much
greater than that by Hmu O.
In the H2O2 reaction with the hemin-HO complex,
deprotonation of the peroxide by a distal group in the heme pocket
facilitates its binding to the hemin iron (38). If the deprotonation is deficient, formation of the active intermediate ferric hydroperoxide is
hindered, and consequently, verdoheme recovery is reduced. Based on
this, one possible reason for the decreased verdohemin recovery in Hmu
O is that the active-site structure, namely the nature of the distal
group, of Hmu O differs from that of rat HO-1.
Structural differences in the distal heme pocket between Hmu O and rat
HO-1 might also explain our observation of the slow ascorbic
acid-supported heme degradation by Hmu O. In the first segment of the
proposed Hmu O catalytic pathway, ascorbic acid reduces the hemin iron
to the ferrous state, thus permitting O2 to bind to the
iron to form a metastable ferrous oxy Hmu O complex. The bound
O2 in HO-1 forms a hydrogen bond with a distal group (39).
This hydrogen bond facilitates the formation of the ferric hydroperoxide active species by decreasing the reduction potential of
the oxy form. The structure of the distal heme pocket of Hmu O might
perturb the hydrogen bond interaction between the bound O2
and a distal group so that the reduction potential of the ferrous oxy
Hmu O complex is altered, thereby reducing the rate of ferric hydroperoxide formation. Consequently, the turnover of Hmu O is retarded when ascorbic acid is used as the source of the reducing equivalents.
Conclusion--
Utilizing a full-length synthetic hmu O
gene, we have expressed in high yield a recombinant bacterial heme
oxygenase that is catalytically identical to the cloned Hmu O from
C. diphtheriae. We have found similarities between Hmu O and
the mammalian HO in terms of enzymatic properties. As with the
mammalian HO, under aerobic conditions and in the presence of an
electron donor, Hmu O catalyzes heme degradation and yields biliverdin
as the final product. Verdoheme is demonstrated to be the immediate
precursor to the biliverdin complex in both the degradation of the
hemin-Hmu O complex and the oxidation of a verdoheme IX
However, despite these similarities, there are differences between Hmu
O and mammalian HO. Among them are the higher affinity of Hmu O for
biliverdin, the formation of biliverdin instead of an
Fe3+-biliverdin complex in the reaction with ascorbic acid,
and the different rate of heme catabolism by Hmu O as compared with rat HO-1. We propose that the distal pocket hydrogen bonding in Hmu O is
different from that in mammalian HO. This might be one primary reason
for the slower overall Hmu O catalytic rate in the ascorbic acid-supported heme degradation and the low verdoheme formation in the
H2O2 reaction. Further investigation of the Hmu
O active site structure and the mechanisms by which heme is catabolized in Hmu O catalysis is needed to explain these differences.
We thank Drs. H. Fujii and C. T. Migita
for the preparation of *
This work was supported by National Institutes of Health
Research Grants GM 57272 and Ministry of Education, Science, Sports, and Culture Grants-in-aid for Scientific Research 09480158, 10129101, and 10044233, Japan.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AB019621.
2
G. C. Chu, T. Tomita, F. Sonnichsen, T. Yoshida, and M. Ikeda-Saito, submitted for publication.
3
These results demonstrate that exogenous CO can
potentially inhibit the conversion of verdoheme to biliverdin by
forming the CO complex of verdoheme-Hmu O. However, CO released during
Hmu O catalysis (23) does not inhibit this conversion in an
air-saturated buffer. One explanation for this is that verdoheme has
extremely low reactivity toward CO because of its inherent ferric
character (36-37). Hence, under physiological conditions, in which the
concentration of CO is much less than that of O2, the
product CO does not inhibit the conversion of verdoheme to biliverdin.
4
CO does not inhibit the conversion of
The abbreviations used are:
HO, heme oxygenase;
mCPBA, meta-chloroperbenzoic acid;
PAGE, polyacrylamide gel electrophoresis;
eq, equivalent(s).
Heme Degradation as Catalyzed by a Recombinant Bacterial Heme
Oxygenase (Hmu O) from Corynebacterium diphtheriae*
,
,
, and
Department of Biochemistry, Yamagata University
School of Medicine, Yamagata 990-9585, Japan
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
-hydroxyhemin and verdoheme as intermediates. The overall conversion
rate to biliverdin is approximately 4-fold slower than that by rat heme
oxygenase (HO) isoform 1. Reaction of the hemin-Hmu O complex with
hydrogen peroxide yields a verdoheme species, the recovery of which is
much less compared with rat HO-1. Reaction of the hemin complex with
meta-chloroperbenzoic acid generates a ferryl oxo species.
Thus, the catalytic intermediate species and the nature of the active
form in the first oxygenation step of Hmu O appear to be similar to
those of the mammalian HO. However, the considerably slow catalytic
rate and low level of verdoheme recovery in the hydrogen peroxide
reaction suggest that the active-site structure of Hmu O is different
from that of its mammalian counterpart.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
, iron, and CO in the presence of NADPH and
NADPH-cytochrome P-450 reductase, which serves as an electron donor
(1-5). Not a hemoprotein per se, HO binds heme at a 1:1
ratio and utilizes it as both a substrate and a prosthetic group
(2-6).
with
-meso-hydroxyheme and verdoheme as intermediates (Scheme
1) (3-5). The CO released during HO
catalysis has been reported to act as a messenger molecule, participating in neuronal transmission and vascular regulation through
the activation of soluble guanylyl cyclase (9-11). The product
biliverdin is subsequently converted to bilirubin by biliverdin reductase (2, 12-13). The significant outcome of this is the removal
of excess heme via the excretion of bilirubin and the recycling of iron
(14).

View larger version (26K):
[in a new window]
Scheme I.
Intermediates in the conversion of heme to
biliverdin as catalyzed by the mammalian heme oxygenase.
and CO upon the aerobic
addition of electron donors. However, the oxygen activation mechanisms and the catalytic pathway of Hmu O are not clear. Whether or not they
are similar to the mammalian system remains to be established.
-hydroxyhemin-, and verdoheme-complexes of the purified recombinant
Hmu O. Reactions of the hemin-Hmu O complex with
H2O2 and mCPBA have also been studied. We have found that the nature of the active form in the first
oxygenation step and the catalytic intermediates of Hmu O are similar
to those of the mammalian HO. However, the distal heme pocket structure
of Hmu O appears to be different from that of its mammalian counterpart.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
--
Plasmid purification, subcloning, and
bacterial transformations were performed according to Sambrook et
al. (24). A T7 promoter-based expression vector, pMW172, was a
gift from Dr. K. Nagai (MRC Laboratory of Molecular Biology, Cambridge,
UK). A 48-base pair double-stranded synthetic oligonucleotide with
unique restriction enzyme sites for XhoI, ClaI,
and AvrII was incorporated between the NdeI and HindIII sites in the multiple cloning site of pMW172 to make
pMWA. Eight oligonucleotides and their complements, 82-91 nucleotides in length, were synthesized to prepare a 648-base pair synthetic gene
coding for the entire Hmu O from the initiator ATG to the TAA stop
codon. Each oligonucleotide was phosphorylated with a T4
polynucleotide kinase, then annealed with its complement to make a
double-stranded DNA, e.g. Oligo I to Oligo VIII. Oligos I
and II were designed so that the 5' end of Oligo I could be ligated to
the NdeI site, whereas its 3' end was complementary to the
5' end of Oligo II. The 3' end of Oligo II could be ligated to the
XhoI site. Similarly, the 5' ends of Oligos III, V, and VII
were designed to ligate to the XhoI, ClaI, and
AvrII sites, respectively, and their 3' ends had sequences
complementary to the 5' ends of Oligos IV, VI, and VIII, respectively.
The 3' ends of Oligos IV, VI, and VIII had sequences for ligation to
the ClaI, AvrII, and HindIII sites.
Given these Oligos I to VIII, the construction of pMWHmuO was as followed.

View larger version (55K):
[in a new window]
Fig. 1.
Nucleotide and amino acid sequences of the
synthesized pMWHmuO as compared with hmu O. The
nucleotide sequence of the cloned hmu O is shown below the
amino acid sequence of the synthetic Hmu O enzyme. The arabic
numerals above the sequence indicate the numbering of the
nucleotide and amino acid sequences.
--
A 10-ml inoculum in
LB-Amp media of A600 nm 1.0 was prepared with a
fresh colony of E. coli BL21 (DE3) cells transformed with
the expression construct pMWHmuO. 500-ml cultures were inoculated with
1 ml of the prepared inocula and grown in LB-Amp media at 37 °C
until A600 nm reached 1.3-1.4. The cells were
grown for an additional 16 h at 25 °C before being harvested by
centrifugation and stored at
80 °C until use. Typically, 2 g
of cells were obtained from a 500-ml culture.
--
250 µM
hemin in 5-µl increments was added to 10 µM of Hmu O in
800 µl of 0.1 M phosphate buffer, pH 7, at 20 °C.
After each addition of hemin, the absorption spectrum was recorded. By
plotting the absorbance at 404 nm against the amount of hemin added,
titration curves were constructed, and the amount of hemin required to
form the hemin-Hmu O complex was determined. To ensure that all Hmu O
were hemin-bound, hemin of concentration twice that of Hmu O was added
to the purified protein solution. After incubation at 4 °C, the
excess hemin was removed by a DEAE-cellulose column. Fractions with
A404 nm/A280 nm greater
than or equal to 3 were collected, concentrated by ultrafiltration, and
stored at 77 K until use.
-meso-Hydroxyhemin- and Verdoheme-Hmu O
Complexes--
Verdoheme (protoverdoheme-IX
) was synthesized as
described by Saito and Itano (25).
-Hydroxyhemin
(
-meso-hydroxyprotohemin) was made by hydrolyzing
-meso-benzoyloxyprotohemin as described previously (26).
The ferric
-hydroxyheme- and ferrous verdoheme-Hmu O complexes were
prepared as described by Mansfield Matera et al. (26) and
Fujii (27), respectively.
--
Heme degradation catalyzed by Hmu O was studied using
ascorbic acid as the electron donor (12). Ascorbic acid of final
concentration 17.5 mM was added to an optical cuvette
containing 10 µM hemin-Hmu O in 2.3 ml of 0.1 M phosphate buffer, pH 7, at 20 °C. Spectral changes
between 300-800 nm were recorded until the reaction was complete, as
indicated by the maximum loss of the Soret band
(A404 nm) and the formation of biliverdin.
--
Preparation for the
assays of the hemin-Hmu O complex with H2O2 and
mCPBA was similar to that described previously (29). Reagent
grade 30% H2O2 was diluted in 0.1 M phosphate buffer, pH 7, to make working solutions, the
concentrations of which were determined spectroscopically using
240 nm = 43.6 M
1·cm
1 (30). The appropriate
amount of H2O2 was added to separate solutions
containing the hemin-Hmu O complex in 0.1 M phosphate buffer, pH 7, to yield final H2O2:hemin-Hmu O
ratios of 1:1, 2:1, 3:1, and 5:1. mCPBA:hemin-Hmu O of these
final concentration ratios were also prepared. Reactions at these
different concentration ratios were monitored spectroscopically at
20 °C.
--
Protein expression and purity were
analyzed by SDS-PAGE on 10-20% gradient gels. The isoelectric point
of the purified Hmu O was determined by a Pharmacia FastSystem
following the manufacturer's instruction. Optical absorption spectra
were recorded on a Hewlett-Packard 8453 spectrophotometer at 20 °C
in 0.1 M phosphate buffer, pH 7.
![]()
RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
--
Sligar and co-workers
(31) have pioneered the use of synthetic genes for bacterial expression
of hemoproteins. The advent of efficient and inexpensive synthesis has
made it feasible to obtain longer (80-90-mer) oligonucleotides than
those (~20 mer) used earlier (31). In our approach here, using longer
oligonucleotides has enabled us to ligate the eight double-stranded
oligonucleotides (Oligos I to VIII) to the expression vector in minimal
ligation steps. The ligation products generated during the plasmid
preparation were conveniently purified by standard agarose gel
electrophoresis, and the final expression plasmid was readily obtained.
Furthermore, the synthetic gene has allowed for the incorporation of
unique restriction enzyme sites convenient for cassette mutagenesis.

View larger version (47K):
[in a new window]
Fig. 2.
SDS-PAGE analysis of the recombinant Hmu O
protein. Lane 1, molecular mass markers; lane 2,
Hmu O expressed in E. coli; lane 3, purified Hmu
O.
--
Fig.
3 shows the optical absorption spectra of
the purified recombinant Hmu O (broken line) and its
stoichiometric complex with hemin (solid line). The optical
absorption spectrum of the hemin-Hmu O complex at pH 7 has a Soret
maxima at 404 nm and peaks at 500 and 630 nm in the visible region
(Fig. 3, solid line). The absorption spectrum is similar to
those of the mammalian hemin-HO complexes and indicates that the
hemin-Hmu O complex is ferric hexacoordinate high spin at neutral pH,
which is the case for the mammalian HO isoforms (5, 33-34). EPR and
resonance Raman spectra of the hemin-Hmu O complex have confirmed
this.2

View larger version (20K):
[in a new window]
Fig. 3.
Optical absorption spectra of Hmu O
(broken line) and its hemin complex (solid
line). The protein concentration was 10 µM. Inset, titration of Hmu O (10 µM) with hemin as monitored by the absorbance increase at
404 nm (closed circles). The absorbance increase because of
the addition of hemin in the absence of Hmu O is indicated by
open circles.
1·cm
1, larger than the 121 mM
1·cm
1 value reported by
Wilks and Schmitt (23). Our value of 150 mM
1·cm
1 is within the range
of Soret extinction coefficients for hexacoordinate high spin
protohemin complexes including the hemin complex of rat HO-1 (165 mM
1·cm
1) (34).
--
Ascorbic acid can serve as the electron donor in the
oxidative degradation of hemin by mammalian HO (12). In this study, ascorbic acid is shown to support the Hmu O-catalyzed conversion of
hemin to biliverdin. As depicted in Fig.
4, the addition of ascorbic acid to the
hemin-Hmu O complex initiates heme degradation. In a period of 2 h, the Soret peak at 404 nm disappears, and broad absorption bands
centered near 380 and 680 nm appear, indicating that hemin is converted
to biliverdin (Fig. 4, spectrum b). Independently, by high
performance liquid chromatography analysis, we have confirmed biliverdin-IX
formation. We have noticed that heme degradation by
Hmu O is 4-fold slower than that by rat HO-1 when ascorbic acid is used
as an electron donor.

View larger version (22K):
[in a new window]
Fig. 4.
Reaction of the hemin-Hmu O complex with
ascorbic acid. The spectra were recorded immediately before the
addition of ascorbic acid, 1, 3, 6, 10, 16, 22, 33 min and 2 h
after the addition of ascorbic acid. Before the addition of ascorbic
acid, the Soret absorbance at 404 nm is maximum. After the addition of
ascorbic acid, the Soret decreases with time, and the absorbance at 680 nm increases. The shoulder near 395 nm in the 2 h spectrum is
because of residual verdoheme. The visible region is expanded for the
spectrum before (spectrum a) and 2 h after
(spectrum b) the addition of ascorbic acid.
--
Heme catabolism catalyzed by mammalian HO yields
biliverdin with verdoheme as a precursor (28). When the hemin-HO
complex is incubated with reducing equivalents under an atomosphere of O2 and CO, heme degradation can be arrested by CO at the
verdoheme stage, resulting in an accumulation of the ferrous
verdoheme-CO complex and thus inhibiting biliverdin formation (28-29).
In our current study of Hmu O catalysis, we have conducted the reaction of the hemin-Hmu O complex with ascorbic acid in an atmosphere of
approximately 50% CO and 50% O2. The product formed
exhibits an absorption spectrum with distinct peaks at 351, 404, 538, and 636 nm, as indicated in Fig.
5A, spectrum a. The
spectrum is similar to that of the CO-bound ferrous verdoheme-rat HO-1
complex (36). With the addition of 20% pyridine, a new spectrum with
peaks at 398, 417, 537, and 679 nm appears (data not shown). This
spectrum resembles that of the pyridine complex of verdoheme-HO-1
(28).

View larger version (21K):
[in a new window]
Fig. 5.
Formation of the CO bound verdoheme-Hmu O
species with CO. Panel A (top), reaction of the hemin-Hmu O
complex with ascorbic acid in the presence of CO. Under an atmosphere
of 50% CO and 50% O2, Hmu O catalysis forms a species
with spectrum a. Exposure of this species to 100%
O2 yields a final product having spectrum b. Spectrum
c is of the biliverdin complex formed in Hmu O catalysis in the
presence of air only. Panel B (bottom), optical absorption
spectra of the CO (spectrum a) and ferrous deoxy
(spectrum b) forms of the verdoheme IX
-Hmu O complex,
prepared from chemically synthesized verdoheme IX
and Hmu O.
-Hmu O,
shown in Fig. 5B, spectrum a, has peaks at 352, 405, 541, and 634 nm, similar to those aforementioned of the
verdoheme-CO intermediate formed during Hmu O catalysis (Fig.
5A, spectrum a). The removal of the
bound CO by evacuation results in the ferrous deoxy verdoheme IX
-Hmu
O complex, whose optical absorption spectrum (Fig. 5B,
spectrum b) has a Soret peak at 400 nm and bands
at 532 and 685 nm. The spectrum is similar to those of the mammalian HO
verdoheme complexes (28, 36). Subsequent exposure of this ferrous
verdoheme IX
-Hmu O complex to O2 and ascorbic acid leads to its conversion to biliverdin (data not shown). These results unequivocally demonstrate verdoheme as the precursor to biliverdin.
-meso-Hydroxyhemin-Hmu O Complex with
O2--
In HO catalysis,
-meso-hydroxyheme
is the precursor to verdoheme (3-5, 26). To determine whether or not
it is an intermediate as well as a precursor to verdoheme in Hmu
O-mediated heme catabolism, we have prepared
-meso-hydroxyhemin-Hmu O using chemically synthesized
-meso-hydroxyhemin and studied its reactivity with
O2. As depicted in Fig. 6,
spectrum a, the optical absorption spectrum of
the
-meso-hydroxyhemin-Hmu O complex exhibits a broad
Soret peak at 404 nm with a relatively featureless visible region,
similar to that of the
-meso-hydroxyhemin-HO complex
(26). Upon addition of dithionite, the heme iron is reduced, thus
forming a ferrous
-hydroxyheme-Hmu O complex (Fig. 6,
spectrum b) with a Soret maxima at 430 nm. The
binding of exogenous CO to this complex yields the CO form of the
ferrous
-hydroxyheme-Hmu O complex, whose spectrum has a distinct
Soret peak at 418 nm (Fig. 6, spectrum c). The
optical absorption spectra of the ferric, ferrous, and ferrous CO forms
of the
-meso-hydroxyheme-Hmu O complex are similar to
those of the respective forms of the
-meso-hydroxyheme
complex of HO-1 (26). Based on these results, we infer that the
coordination structure and electronic states of the
-hydroxyheme-Hmu
O complexes are pentacoordinate high spin for the ferric and ferrous
forms and hexacoordinate low spin for the ferrous CO form, concurring with those established for the
-hydroxyheme complexes of HO-1 (26).

View larger version (17K):
[in a new window]
Fig. 6.
Optical absorption spectra of the
-hydroxyheme-Hmu O complex and its reaction
products. The initially ferric complex (spectrum a) was
reduced anaerobically to the ferrous form (spectrum b) by
dithionite and then coordinated with CO, forming the ferrous-CO
derivative (spectrum c). Reaction of the ferrous CO
-hydroxyheme-Hmu O with O2 resulted in spectrum
d.
-hydroxyheme-Hmu O with
O2 causes an immediate shift of the Soret band to 404 nm,
and a defined peak at 634 nm emerges (Fig. 6, spectrum
d). This is similar to HO-1 (26). The optical absorption
spectrum of the newly formed species is identical to that we have
observed for CO-bound verdoheme-Hmu O.4 Prolonged exposure of the
aforementioned species to O2 in the presence of ascorbic
acid produces an optical spectrum similar to that of a biliverdin
complex (data not shown). The results described above undeniably
demonstrate that
-hydroxyheme is an intermediate of the Hmu
O-mediated heme degradation, specifically as the precursor to verdoheme.
-hydroxyhemin, the hemin-HO-1
complex was reacted with mCPBA (29). This resulted in the
formation of the ferryl oxo species (Fe4+=O). In our
current Hmu O study, reaction of the hemin-Hmu O complex with
mCPBA causes a decrease and a shift in the Soret peak from 404 to 418 nm and the concomitant appearance of absorption bands at 527 and 549 nm (Fig. 7). The spectrum is
characteristic of the ferryl oxo-heme species (29, 33). No further heme
degradation occurred hereafter. Hence, ferryl oxo is not an active
intermediate in Hmu O catalysis.

View larger version (15K):
[in a new window]
Fig. 7.
Reaction of the hemin-Hmu O complex with
mCPBA. a, spectrum of the hemin-Hmu O
complex; b, spectrum after the addition of 3 eq of
mCPBA.
-meso position of hemin to form
-meso-hydroxyhemin, which then is converted to verdohemin
in the presence of O2 (29). Here we have reacted the
hemin-Hmu O complex with H2O2 and found that a
verdohemin complex, as indicated by the absorption band at 688 nm (Fig.
8A), is formed. This
verdohemin formation was further corroborated by the optical absorption
spectrum of its pyridine complex (data not shown). Based on these
results, a ferric hydroperoxide species must be an active intermediate
in the first oxygenation step of Hmu O catalysis as it is in mammalian
HO.

View larger version (28K):
[in a new window]
Fig. 8.
Reactions of the hemin-Hmu O and hemin-rat
HO-1 complexes with H2O2. Panel A
(top), spectra of the hemin-Hmu O complex ( 



) after
the addition of 1 eq (- - - - - -), 2 eq
(- · - · -), 3 eq (
), and 5 eq
(- · · - · ·) of
H2O2. Panel B (bottom), spectra of
the hemin-rat HO-1 complex (



) after the addition
of 1 eq (- - - - - -), 2 eq
(- · - · -), 3 eq (
), and 5 eq
(- · · - · ·) of
H2O2.
-Hmu O
complex prepared from a chemically synthesized verdoheme and Hmu O. When the
-hydroxyheme-Hmu O complex we have prepared is oxidized in
the presence of a reductant, verdoheme and subsequently a biliverdin
complex, are formed. In addition, we have found that a ferric
hydroperoxide species is an active intermediate of the first
oxygenation step in Hmu O catalysis. These results and that of a
previous study, which showed CO being concomitantly released during Hmu
O catalysis (23), suggest that the Hmu O catalytic pathway is similar
to that of mammalian HO.
![]()
ACKNOWLEDGEMENTS
-meso-hydroxyhemin and verdoheme
and Dr. S. Park for pI measurements.
![]()
FOOTNOTES
-hydroxyheme to verdoheme in Hmu O catalysis. As reported for HO-1,
this conversion appears to proceed without the dissociation of CO from
the
-hydroxyheme iron. Direct oxygen attack of the porphyrin ring
may be an alternative mechanism (26).
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
1.
Tenhunen, R.,
Marver, H. S.,
and Schmid, R.
(1969)
J. Biol. Chem.
244,
6388-6394 2.
Maines, M. D.
(1988)
FASEB J.
2,
2557-2568[Abstract]
3.
Sono, M.,
Roach, M. P.,
Coulter, E. D.,
and Dawson, J. H.
(1996)
Chem. Rev.
96,
2841-2887[CrossRef][Medline]
[Order article via Infotrieve]
4.
Ortiz de Montellano, P. R.
(1998)
Acc. Chem. Res.
31,
543-549[CrossRef]
5.
Ikeda-Saito, M.,
Fujii, H.,
Mansfield Matera, K.,
Takahashi, S.,
Migita, C. T.,
and Yoshida, T.
(1998)
in
Oxygen Homeostasis and Its Dynamics
(Ishimura, Y.
, Shimada, H.
, and Suematsu, M., eds)
, pp. 304-314, Springer-Verlag, Tokyo
6.
Yoshida, T.,
and Kikuchi, G.
(1978)
J. Biol. Chem.
253,
4224-4229 7.
Schacter, B. A.,
Nelson, E. B.,
Marver, H. S.,
and Masters, B. S. S.
(1972)
J. Biol. Chem.
247,
3601-3607 8.
Yoshida, T.,
Noguchi, M.,
and Kikuchi, G.
(1980)
J. Biol. Chem.
255,
4418-4420 9.
Verma, A.,
Hirsch, D. J.,
Glatt, C. E.,
Ronnett, G. V.,
and Snyder, S. H.
(1993)
Science
259,
381-384 10.
Nathanson, J. A.,
Scavone, C.,
Scanlon, C.,
and McKee, M.
(1995)
Neuron
14,
781-794[CrossRef][Medline]
[Order article via Infotrieve]
11.
Zakhary, R.,
Gaine, S. P.,
Dinerman, J. L.,
Ruat, M.,
Flavahan, N. A.,
and Snyder, S. H.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
795-798 12.
Yoshida, T.,
and Kikuchi, G.
(1978)
J. Biol. Chem.
253,
4230-4236 13.
Docherty, J. C.,
Schacter, B. A.,
Firneisz, G. D.,
and Brown, S. B.
(1984)
J. Biol. Chem.
259,
13066-13069 14.
Poss, K. D.,
and Tonegawa, S.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
10919-10924 15.
Schmitt, M. P.,
and Holmes, R. K.
(1994)
J. Bacteriol.
176,
1141-1149 16.
Tao, X.,
Schiering, N.,
Zeng, H.,
Ringe, D.,
and Murphy, J. R.
(1994)
Mol. Microbiol.
14,
191-197[Medline]
[Order article via Infotrieve]
17.
Lee, B. C.
(1995)
Mol. Microbiol.
18,
383-390[CrossRef][Medline]
[Order article via Infotrieve]
18.
Stojiljkovic, I.,
and Hantke, K.
(1992)
EMBO J.
11,
4359-4367[Medline]
[Order article via Infotrieve]
19.
Mills, M.,
and Payne, S. M.
(1995)
J. Bacteriol.
177,
3004-3009 20.
Braun, V.
(1997)
Biol. Chem.
378,
779-786[Medline]
[Order article via Infotrieve]
21.
Stojiljkovic, I.,
and Hantke, K.
(1994)
Mol. Microbiol.
13,
719-732[Medline]
[Order article via Infotrieve]
22.
Schmitt, M. P.
(1997)
J. Bacteriol.
179,
838-845 23.
Wilks, A.,
and Schmitt, M. P.
(1998)
J. Biol. Chem.
273,
837-841 24.
Sambrook, J.,
Fritsch, E. F.,
and Maniatis, T.
(1989)
Molecular Cloning: A Laboratory Manual
, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
25.
Saito, S., and Itano, H. A. (1986) J. Chem. Soc. Perkin
Trans. pp. 1-7
26.
Mansfield Matera, K.,
Takahashi, S.,
Fujii, H.,
Zhou, H.,
Ishikawa, K.,
Yoshimura, T.,
Rousseau, D. L.,
Yoshida, T.,
and Ikeda-Saito, M.
(1996)
J. Biol. Chem.
271,
6618-6224 27.
Fujii, H.
(1990)
Studies on the Electron Structure and Reactivities of Catalytic Intermediates in Heme Enzymes.Ph.D. thesis
, Kyoto University
28.
Yoshida, T.,
Noguchi, M.,
and Kikuchi, G.
(1980)
J. Biochem. (Tokyo)
88,
557-563 29.
Wilks, A.,
and Ortiz de Montellano, P. R.
(1993)
J. Biol. Chem.
268,
22357-22363 30.
Beers, R. F., Jr.,
and Sizer, I. W.
(1952)
J. Biol. Chem.
195,
133-140 31.
Stayton, P. S.,
Atkins, W. M.,
Springer, B. A.,
and Sligar, S. G.
(1989)
in
Metal Ion in Biological Systems
(Sigel, H., ed), Vol. 25
, pp. 417-475, Marcel Dekker, Inc., New York, NY
32.
Mansfield Matera, K.,
Zhou, H.,
Migita, C. T.,
Hobert, S. E.,
Ishikawa, K.,
Katakura, K.,
Maeshima, H.,
Yoshida, T.,
and Ikeda-Saito, M.
(1997)
Biochemistry
36,
4909-4915[CrossRef][Medline]
[Order article via Infotrieve]
33.
Ishikawa, K.,
Takeuchi, N.,
Takahashi, S.,
Matera, K. M.,
Sato, M.,
Shibahara, S.,
Rousseau, D. L.,
Ikeda-Saito, M.,
and Yoshida, T.
(1995)
J. Biol. Chem.
270,
6345-6350 34.
Takahashi, S.,
Wang, J.,
Rousseau, D. L.,
Ishikawa, K.,
Yoshida, T.,
Host, J. R.,
and Ikeda-Saito, M.
(1994)
J. Biol. Chem.
269,
1010-1014 35.
Paul, K. G.,
Theorell, H.,
and Akeson, A.
(1953)
Acta Chem. Scand.
7,
1284-1287
36.
Takahashi, S.,
Mansfield Matera, K.,
Fujii, H.,
Zhou, H.,
Ishikawa, K.,
Yoshida, T.,
Ikeda-Saito, M.,
and Rousseau, D. L.
(1997)
Biochemistry
36,
1402-1410[CrossRef][Medline]
[Order article via Infotrieve]
37.
Migita, C. T.,
Mansfield Matera, K.,
Ikeda-Saito, M.,
Olson, J. S.,
Fujii, H.,
Yoshimura, T.,
Zhou, H.,
and Yoshida, T.
(1998)
J. Biol. Chem.
273,
945-949 38.
Wilks, A.,
Ortiz de Montellano, P. R.,
Sun, J.,
and Loehr, T. M.
(1996)
Biochemistry
35,
930-936[CrossRef][Medline]
[Order article via Infotrieve]
39.
Fujii, H.,
Dou, Y.,
Zhou, H.,
Yoshida, T.,
and Ikeda-Saito, M.
(1998)
J. Am. Chem. Soc.
120,
8251-8252[CrossRef]
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
M. D. L. Suits, N. Jaffer, and Z. Jia Structure of the Escherichia coli O157:H7 Heme Oxygenase ChuS in Complex with Heme and Enzymatic Inactivation by Mutation of the Heme Coordinating Residue His-193 J. Biol. Chem., December 1, 2006; 281(48): 36776 - 36782. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Ridley, J. D. Rock, Y. Li, and J. M. Ketley Heme Utilization in Campylobacter jejuni J. Bacteriol., November 15, 2006; 188(22): 7862 - 7875. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Ueno, N. Yokoi, M. Unno, T. Matsui, Y. Tokita, M. Yamada, M. Ikeda-Saito, H. Nakajima, and Y. Watanabe Design of metal cofactors activated by a protein-protein electron transfer system PNAS, June 20, 2006; 103(25): 9416 - 9421. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. L. Suits, G. P. Pal, K. Nakatsu, A. Matte, M. Cygler, and Z. Jia Identification of an Escherichia coli O157:H7 heme oxygenase with tandem functional repeats PNAS, November 22, 2005; 102(47): 16955 - 16960. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Wang, L. Lad, T. L. Poulos, and P. R. O. de Montellano Regiospecificity Determinants of Human Heme Oxygenase: DIFFERENTIAL NADPH- AND ASCORBATE-DEPENDENT HEME CLEAVAGE BY THE R183E MUTANT J. Biol. Chem., January 28, 2005; 280(4): 2797 - 2806. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Matsui, M. Furukawa, M. Unno, T. Tomita, and M. Ikeda-Saito Roles of Distal Asp in Heme Oxygenase from Corynebacterium diphtheriae, HmuO: A WATER-DRIVEN OXYGEN ACTIVATION MECHANISM J. Biol. Chem., January 28, 2005; 280(4): 2981 - 2989. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Unno, T. Matsui, G. C. Chu, M. Couture, T. Yoshida, D. L. Rousseau, John. S. Olson, and M. Ikeda-Saito Crystal Structure of the Dioxygen-bound Heme Oxygenase from Corynebacterium diphtheriae: IMPLICATIONS FOR HEME OXYGENASE FUNCTION J. Biol. Chem., May 14, 2004; 279(20): 21055 - 21061. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Hirotsu, G. C. Chu, M. Unno, D.-S. Lee, T. Yoshida, S.-Y. Park, Y. Shiro, and M. Ikeda-Saito The Crystal Structures of the Ferric and Ferrous Forms of the Heme Complex of HmuO, a Heme Oxygenase of Corynebacterium diphtheriae J. Biol. Chem., March 19, 2004; 279(12): 11937 - 11947. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. P. Skaar, A. H. Gaspar, and O. Schneewind IsdG and IsdI, Heme-degrading Enzymes in the Cytoplasm of Staphylococcus aureus J. Biol. Chem., January 2, 2004; 279(1): 436 - 443. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Protchenko and C. C. Philpott Regulation of Intracellular Heme Levels by HMX1, a Homologue of Heme Oxygenase, in Saccharomyces cerevisiae J. Biol. Chem., September 19, 2003; 278(38): 36582 - 36587. [Abstract] [Full Text] [PDF] |
||||